Extensions — US Patent 11610226

Based on an analysis of the prosecution history and family data for US patent 11,610,226 from the provided authoritative patent text and associated USPTO records, here are the details regarding its term, continuity, and related applications.

Patent Term and Expiration

Patent Term Adjustment (PTA): There are no recorded Patent Term Adjustments for US patent 11,610,226. The patent was granted a PTA of 0 days.
Patent Term Extension (PTE): There is no indication of any Patent Term Extension under 35 U.S.C. § 156, which typically applies to patents for products that undergo lengthy regulatory review (e.g., pharmaceuticals) and is not applicable here.
Projected Expiration Date: The patent's term is calculated from the filing date of the earliest non-provisional application in its priority chain, which is US application Ser. No. 11/763,286, filed on June 14, 2007. The standard 20-year term therefore ends on June 14, 2027. As there is no PTA, the projected expiration date is June 14, 2027. This is confirmed by the "Adjusted expiration" date listed in the patent details (Source: https://patents.google.com/patent/[US11610226](/patent/US11610226)/en).

Continuity and Family Data

This patent is part of a large and long-prosecuted family of applications that all claim priority to the same provisional applications filed in 2006.

Continuation Applications: US patent 11,610,226 is a continuation of a long chain of prior applications. The direct parent is application Ser. No. 17/097,865 (now US Patent 11,301,898). The full chain of priority is detailed in the "Cross Reference to Related Applications" section of the patent specification.

Furthermore, this patent serves as the basis for at least one subsequent continuation application:
- US Application 18/122,654 (now US Patent 11,836,759), filed on March 16, 2023, is a continuation of the application that led to US patent 11,610,226 (Source: https://patents.google.com/patent/[US11610226](/patent/US11610226)/en).
Divisional Applications: No divisional applications have been identified in the prosecution history of this patent family. The applicant has exclusively used continuation applications to pursue additional claims.
Patent Family Members: US patent 11,610,226 is one of at least 14 granted US patents in this family, all sharing the same 2007 priority date. Other issued patents in this family include:

The extensive use of continuation applications has allowed the assignee, Almondnet Inc., to create a large portfolio of patents with varied claim scope, all tied to the original 2006/2007 priority filings.